PrecisemAb Biotech CO., LTD.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
Our Universal Antibody Lock™ is an innovative proprietary platform designed to generate conditionally-activated antibody therapeutics for various antibody formats, including monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. This technology enhances antibody selectivity while reducing on-target toxicity, providing safer and more effective treatment solutions for patients.
Founded Year
2021
Unified Business No.
90663465
Status
Active
Number of Employees
0
Total Paid-in
Capital
69,100,000 (NT$)
Location of Company
Taiwan
, Taipei City
Overseas Development
Japan、Korea, Republic of
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
PrecisemAb Biotech develops safer antibody therapeutics using its patented Antibody Lock™ platform, enabling tumor microenvironment–specific activation to reduce systemic toxicity. Protected in 18 countries and licensed to GlycoNex in 2024, the platform is expanding into bispecifics and ADCs, with proprietary asset PSM101 targeting IND submission in 2027.
